首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1532402

免疫腫瘤藥物市場：依治療類型、疾病類型、通路、地區分類

Immuno-oncology Drugs Market, By Treatment Type, By Disease Type, By Distribution Channel, By Geography

出版日期: 2024年07月16日 | 出版商:

Coherent Market Insights | 英文 188 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年全球免疫腫瘤藥物市場規模為272.5億美元，預計2031年將達891億美元，2024年至2031年複合年成長率為18.4%。

報告範圍		報告詳情
基準年	2023年	2024年市場規模	272.5億美元
實際資料	2019-2023	預測期	2024年至2031年
預測 2024-2031 年複合年成長率：	18.40%	2031年價值預測	891億美元

圖：2024 年按地區分類的免疫腫瘤藥物市場佔有率（%）

免疫腫瘤藥物利用人體的免疫系統來對抗癌症，並已被證明可以提高多種癌症類型的存活率。這些藥物增強針對癌細胞的免疫反應，並提高存活率。主要核准的免疫腫瘤藥物類別包括查核點抑制劑、癌症疫苗和特異性免疫療法。不斷臨床研究和開發具有更高功效和安全性的新藥正在推動市場成長。

市場動態：

全球免疫腫瘤藥物市場的成長主要是由全球癌症發生率上升所推動的。由於生活型態的改變、預期壽命的延長、污染等環境因素，癌症發生率逐年上升。與傳統癌症治療相比，免疫腫瘤藥物已證明具有長期療效和存活率。這正在促進藥物研發並增加藥物核准。伴同性診斷的發展將透過識別最適合免疫治療的患者群體來推動市場成長。然而，這些藥物的高成本可能會限制其在價格敏感地區的採用。此外，免疫相關副作用等安全問題也可能阻礙市場成長。正在進行的評估新適應症、藥物組合和個人化療法的臨床試驗可能會在不久的將來為市場成長提供利潤豐厚的機會。

本研究的主要特點

該報告對全球免疫腫瘤藥物市場進行了詳細分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模（十億美元）和年複合成長率（CAGR%）。正在做。
它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
它根據公司亮點、產品系列、主要亮點、財務表現和策略等參數，介紹了全球免疫腫瘤藥物市場的主要企業。
該報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球免疫腫瘤藥物市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球免疫腫瘤藥物市場的各種策略矩陣，將有助於相關人員做出決策。

公司簡介
- Coloplast Corp
- Bristol Myers Squibb Company
- Novartis AG
- F. Hoffmann-LA Roche Ltd.
- Merck &Co., Inc.
- GSK Plc.
- Eli Lilly and Company
- Fresenius Kabi AG
- Pfizer Inc.
- AbbVie Inc.
- Genentech Inc.
- Sanofi
- AstraZeneca
- Bayer AG
- Bluebird Bio, Inc.
- Regeneron Pharmaceuticals, Inc.
- Amgen Inc.

第10章分析師建議

命運之輪
分析師觀點
一致的機會圖

第11章參考文獻與調查方法

參考
調查方法

簡介目錄

Product Code: CMI1271

Global immuno-oncology drugs market is estimated to be valued at USD 27.25 Bn in 2024 and is expected to reach USD 89.10 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 18.4% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 27.25 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2024 to 2031 CAGR:	18.40%	2031 Value Projection:	US$ 89.10 Bn

Figure. Immuno-oncology Drugs Market Share (%), By Region 2024

Immuno-oncology drugs use the body's immune system to fight cancer, and have demonstrated improved survival rates for various cancer types. These drugs boost the immune response against cancer cells, and thus, improve survival outcomes. Some major immuno-oncology drug classes approved include checkpoint inhibitors, cancer vaccines, and nonspecific immunotherapies. Continued clinical research and development of novel agents with improved efficacy and safety profiles can drive the market growth.

Market Dynamics:

Global immuno-oncology drugs market growth is primarily driven by rising cases of cancer worldwide. Cancer incidence has been rising year-on-year owing to lifestyle changes, increased life expectancy, and environmental factors like pollution. Immuno-oncology drugs have demonstrated long-term efficacy and survival benefits as compared to conventional cancer therapies. This boosts pharmaceutical R&D and increases drug approvals. The developments in companion diagnostics identify patient populations most suitable for immunotherapies, thus, driving the market growth. However, high costs of these drugs can restrict its adoption in price-sensitive regions. Safety issues like immune-related adverse effects can also hamper the market growth. Ongoing clinical trials evaluating new indications, drug combinations, and personalized therapies can offer lucrative opportunities for the market growth in the near future.

Key Features of the Study:

This report provides in-depth analysis of the global immuno-oncology drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global immuno-oncology drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Bristol-Myers Squibb, Merck, Roche, Pfizer, AstraZeneca, and Novartis
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global immuno-oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immuno-oncology drugs market

Detailed Segmentation-

By Treatment Type
- Immune Checkpoint Inhibitors
- PD-1
- PD-LI
- CTLA-4
- Immune System Modulators
- Cancer Vaccines
- Oncolytic Virus
- Others
By Disease Type
- Melanoma
- Lung Cancer
- Blood Cancer
- Renal Cell Carcinoma
- Prostate Cancer
- Bladder Cancer
- Others (Breast Cancer, Thyroid Cancer, etc.)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Coloplast Corp
- Bristol Myers Squibb Company
- Novartis AG
- F. Hoffmann-LA Roche Ltd.
- Merck & Co., Inc.
- GSK Plc.
- Eli Lilly and Company
- Fresenius Kabi AG
- Pfizer Inc.
- AbbVie Inc.
- Genentech Inc.
- Sanofi
- AstraZeneca
- Bayer AG
- Bluebird Bio, Inc.
- Regeneron Pharmaceuticals, Inc.
- Amgen Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Disease Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Acquisitions and Partnerships Scenario
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Immuno-oncology Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Immuno-oncology Drugs Market, By Treatment Type, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Immune Checkpoint Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
PD-1
PD-LI
CTLA-4
Immune System Modulators
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Cancer Vaccines
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Oncolytic Virus
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Immuno-oncology Drugs Market, By Disease Type, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Melanoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Lung Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Blood Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Renal Cell Carcinoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Prostate Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Bladder Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Immuno-oncology Drugs Market, By Distribution Channel, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Immuno-oncology Drugs Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2031
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2019 - 2031, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Coloplast Corp
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Bristol Myers Squibb Company
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- F. Hoffmann-LA Roche Ltd.
- Merck & Co., Inc.
- GSK Plc.
- Eli Lilly and Company
- Fresenius Kabi AG
- Pfizer Inc.
- AbbVie Inc.
- Genentech Inc.
- Sanofi
- AstraZeneca
- Bayer AG
- Bluebird Bio, Inc.
- Regeneron Pharmaceuticals, Inc.
- Amgen Inc.